Calf Thymus DNA Exposed to Quinacrine at Physiological Temperatures and pH Acquires Immunogenicity: A Threat for Long Term Quinacrine Therapy
- PMID: 36262783
- PMCID: PMC9573848
- DOI: 10.1007/s12291-021-01013-9
Calf Thymus DNA Exposed to Quinacrine at Physiological Temperatures and pH Acquires Immunogenicity: A Threat for Long Term Quinacrine Therapy
Abstract
Quinacrine is an Acridine derivative with two potentially reactive groups; a diamino butyl side chain and an Acridine ring both capable of interacting with DNA but in different ways. This is an antimalarial drug approved by FDA for long term clinical trials and for the treatment of other diseases as well. The study evaluates the physicochemical interactions of quinacrine with DNA (calf thymus DNA) through characterizations of quinacrine DNA adduct (Q-DNA) by various techniques. It was observed that quinacrine induces stability in the structure of DNA, as the onset of melting was found to be increased by 6 °C in the melting temperature profile of Q-DNA supported by other data obtained during study, deviation from the native structure of DNA was analyzed by FTIR that showed specific shifts in the region of 1707-1400 cm-1.The study also probed the antigenicity of Q-DNA compared to its non antigenic native counterpart (N-DNA), by using both as antigens in female New Zealand White rabbits. Q-DNA was found to be antigenic with antibody titer > 1:6400. IgG was isolated and characterized to check for binding specificity. These antibodies were found to be promiscuous capable of cross reacting with other cellular molecules. Analysis of the data obtained suggested that intracellular accumulation of quinacrine and its ability to cross nucleus may allow the drug to interact with DNA. This may bring about significant structural perturbations in the macromolecule triggering an immunogenic response at the site where anti Q-DNA antibody and Q-DNA complex accumulates.
Keywords: Antigenicity; DNA; ELISA; Quinacrine.
© The Author(s), under exclusive licence to Association of Clinical Biochemists of India 2021.
Conflict of interest statement
Conflict of interestAuthors have no conflicts of interest to declare that are relevant to this article.
Figures





Similar articles
-
31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA.Biochemistry. 1989 Apr 4;28(7):2804-12. doi: 10.1021/bi00433a010. Biochemistry. 1989. PMID: 2472832
-
The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo.Toxicology. 1996 Jun 17;110(1-3):27-37. doi: 10.1016/0300-483x(96)03319-7. Toxicology. 1996. PMID: 8658557
-
DNA intercalation by quinacrine and methylene blue: a comparative binding and thermodynamic characterization study.DNA Cell Biol. 2008 Feb;27(2):81-90. doi: 10.1089/dna.2007.0652. DNA Cell Biol. 2008. PMID: 17924822
-
A Review on Acridines as Antiproliferative Agents.Mini Rev Med Chem. 2022;22(21):2769-2798. doi: 10.2174/1389557522666220511125744. Mini Rev Med Chem. 2022. PMID: 35546777 Review.
-
Quinacrine: sclerosing agent of the utero-tubal junction in women, with anticarcinogenic actions in transplanted tumors in mice.Int J Gynaecol Obstet. 1995 Dec;51 Suppl 1:S47-55. doi: 10.1016/0020-7292(95)90369-0. Int J Gynaecol Obstet. 1995. PMID: 8904515 Review.
References
-
- Benoit S, Goebeler M. Mepacrine in recalcitrant cutaneous lupus erythematosus: old-fashioned or still useful? Acta DermVenereol. 2015;95(5):596–599. - PubMed
-
- McCune WJ, Gonzalez-Rivera T. Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity? Curr Opin Rheumatol. 2015;27(3):213–215. doi: 10.1097/BOR.0000000000000173. - DOI - PubMed
LinkOut - more resources
Full Text Sources